Discover HOYA MiYOSMART iQ, its DIMS TED technology, 12-month clinical results and benefits for childhood myopia. Coming soon to Malaya Optical.
HOYA MiYOSMART iQ Malaysia: The Next Generation of D.I.M.S. Myopia Control Lenses for Children
Discover HOYA MiYOSMART iQ, featuring Triple Enhanced Design (DIMS TED), its latest 12-month clinical findings, and how Malaya Optical monitors childhood myopia progression in Malaysia.
Your child’s short-sightedness has increased again.
Last year, their spectacle prescription was −1.00D. Now it is −2.00D.
For many Malaysian parents, this raises a concern: Will my child’s eye power keep increasing every year?
While conventional spectacles correct blurry distance vision, modern myopia-management lenses are designed to do more. They aim to slow the progression of short-sightedness during childhood, when the eyes are still growing.
One of the latest developments is HOYA MiYOSMART iQ, a new-generation spectacle lens featuring Defocus Incorporated Multiple Segments Triple Enhanced Design (DIMS TED).
Building on the established technology of the original HOYA MiYOSMART, MiYOSMART iQ introduces three optical enhancements designed to deliver stronger and more extensive myopic-defocus signals.
In clinical results announced in May 2026, HOYA reported that approximately nine out of ten children wearing MiYOSMART iQ experienced no clinically relevant myopia progression over 12 months.
The findings are encouraging, but they require careful interpretation.
HOYA MiYOSMART iQ is coming soon to Malaya Optical Malaysia, with planned availability at our branches in Kuala Lumpur, Damansara Uptown, Subang Jaya and Puchong.
The original MiYOSMART will continue to be offered, giving parents another option to discuss with our optometrists.
In this guide, we explain how MiYOSMART iQ works, what makes its Triple Enhanced Design different, what the clinical research shows and why monitoring eye growth matters.
What Is HOYA MiYOSMART iQ?
HOYA MiYOSMART iQ is a specialised spectacle lens designed to correct childhood short-sightedness while helping slow myopia progression.
It uses an advanced version of HOYA’s established D.I.M.S. technology, developed through research involving HOYA Vision Care and The Hong Kong Polytechnic University.
The newer design is known as DIMS TED — Triple Enhanced Design.
Like ordinary spectacles, MiYOSMART iQ corrects the child’s distance prescription.
However, it also contains specially designed optical treatment segments that create additional myopic-defocus signals.
These signals are intended to influence eye-growth regulation and help slow excessive axial elongation.
MiYOSMART iQ is worn as spectacles, making it an option for children who are not ready for contact lenses.
It does not cure myopia or guarantee that progression will stop. Individual treatment responses vary.
Why Does Childhood Myopia Progression Matter?
Myopia, commonly called short-sightedness, occurs when distant light focuses in front of the retina rather than directly on it.
In many children, this is associated with the eye becoming too long.
As the eyeball elongates, the spectacle prescription may become increasingly negative.
For example, a child may progress from −1.00D to −2.00D and eventually −3.00D.
Some children progress slowly, while others experience more rapid changes.
Higher levels of myopia are associated with increased lifetime risks of conditions such as myopic maculopathy, retinal detachment and glaucoma.
This is why myopia management focuses on more than providing clear vision today.
The objective is to slow excessive eye growth during childhood and potentially reduce the risk of developing higher myopia later in life.
Correcting Myopia vs Managing Myopia
Conventional single-vision spectacles primarily correct blurred distance vision.
Myopia-management spectacles provide the prescribed correction while incorporating additional optical treatment signals.
HOYA MiYOSMART iQ belongs to this second category.
Understanding HOYA D.I.M.S. Technology
D.I.M.S. stands for Defocus Incorporated Multiple Segments.
The original MiYOSMART lens introduced a design combining a central clear optical zone with numerous small treatment segments.
The central zone corrects the child’s distance prescription.
The surrounding segments create additional myopic-defocus signals.
What Is Myopic Defocus?
Myopic defocus refers to an optical condition in which some light focuses in front of the retina.
Researchers believe appropriately designed myopic-defocus signals can help influence the regulation of eye growth.
The goal is to slow excessive axial elongation while maintaining useful vision for everyday activities.
Different myopia-management spectacle lenses use different optical structures to produce these signals.
HOYA’s approach uses multiple small treatment segments.
MiYOSMART iQ builds on that foundation through a redesigned configuration.
What Is DIMS TED? The Three Enhancements in MiYOSMART iQ
The defining feature of MiYOSMART iQ is its Triple Enhanced Design (TED).
HOYA identifies three main improvements.
1. Treatment Segments Positioned Closer to the Centre
MiYOSMART iQ incorporates a smaller central clear zone, allowing the treatment segments to begin closer to the centre of the lens.
The intention is to provide myopic-defocus signals more consistently to the near-peripheral retina.
This region has been investigated for its responsiveness to optical-defocus signals involved in eye-growth regulation.
The design aims to deliver treatment signals during normal eye movements and everyday visual activities.
2. Higher Defocus Power
MiYOSMART iQ uses higher defocus power than the original MiYOSMART design.
This is intended to create a stronger myopic-defocus signal.
Importantly, higher defocus power does not mean the child’s normal spectacle prescription becomes stronger.
The treatment-segment power is separate from the main prescription used to correct distance vision.
3. Extended Treatment Zone
MiYOSMART iQ incorporates a larger treatment area with more defocus segments.
The extended zone is designed to provide broader optical treatment coverage, including when larger spectacle frames are used.
This may help maintain the intended treatment signal across a wider portion of the lens.
Why Do These Improvements Matter?
Together, the three enhancements are intended to improve:
- The positioning of the myopic-defocus signal
- The strength of that signal
- The area over which it is delivered
The underlying objective remains the same: to help slow excessive eye elongation.
However, the optical design is different from the original MiYOSMART.
HOYA MiYOSMART iQ vs Original MiYOSMART: What’s Different?
The original MiYOSMART helped establish D.I.M.S. technology as an important approach to spectacle-based myopia management.
MiYOSMART iQ represents a new-generation technological upgrade within the same lens family.
Importantly, the original MiYOSMART is not being presented here as discontinued or replaced.
Malaya Optical plans to continue offering both options.
| Feature | Original HOYA MiYOSMART | HOYA MiYOSMART iQ |
|---|---|---|
| Optical technology | D.I.M.S. | DIMS Triple Enhanced Design |
| Central clear zone | Original D.I.M.S. configuration | Smaller central zone |
| Treatment-segment positioning | Established arrangement | Segments positioned closer to the centre |
| Defocus power | Original treatment power | Higher defocus power |
| Treatment area | Original treatment zone | Extended treatment zone |
| Clinical evidence | Established multi-year research | Newer 12-month randomized trial findings |
| Contact lens handling | Not required | Not required |
| Primary objective | Slow childhood myopia progression | Slow childhood myopia progression |
Advantages of Original MiYOSMART
Longer clinical evidence history: Original MiYOSMART has been studied over multiple years, providing more information about sustained treatment outcomes.
Established technology: Its D.I.M.S. design has been used internationally for childhood myopia management.
Continued availability: Parents at Malaya Optical will still be able to discuss original MiYOSMART as a treatment option.
Considerations for Original MiYOSMART
Its optical design does not incorporate the three enhancements introduced in MiYOSMART iQ.
As with other myopia-management spectacles, individual responses vary and regular monitoring remains necessary.
Advantages of MiYOSMART iQ
New Triple Enhanced Design: Treatment segments are positioned closer to the centre, with higher defocus power and an extended treatment zone.
Promising clinical results: HOYA reports smaller average changes in prescription and axial length compared with conventional single-vision spectacles.
Research including younger children: The clinical trial included children aged four to twelve.
Considerations for MiYOSMART iQ
Its clinical evidence history is shorter than that of the original MiYOSMART.
The 12-month findings were presented at a scientific conference and reported by HOYA; longer-term peer-reviewed evidence remains important.
The most appropriate lens should be selected based on clinical assessment rather than assuming every child needs the newest design.
Is MiYOSMART iQ Twice as Effective?
In February 2026, HOYA described six-month MiYOSMART iQ findings as showing approximately twice the effectiveness of the original MiYOSMART in controlling myopia progression and axial elongation, based on the comparisons reported.
This is a manufacturer-reported clinical finding, not a promise that every child will experience twice the benefit.
Different study populations, follow-up periods and analysis methods can affect reported treatment effects.
Parents should therefore consider the absolute changes in prescription and axial length, alongside the broader evidence for each lens.
What Does the MiYOSMART iQ Clinical Research Show?
HOYA Vision Care and The Hong Kong Polytechnic University conducted a randomized controlled clinical trial in Hong Kong.
The 12-month findings were presented at the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver.
According to HOYA, 196 children aged 4–12 years completed the randomized controlled trial.
Researchers evaluated two important outcomes.
Spherical Equivalent Refraction (SER): A measure of the child’s refractive prescription, expressed in dioptres (D).
Axial Length (AL): The length of the eye from front to back, expressed in millimetres (mm).
These measurements are particularly important because a child’s spectacle power does not tell the whole story about eye growth.
MiYOSMART iQ 12-Month Clinical Results
HOYA reported the following average changes over one year among children aged 4–12.
| Clinical measurement | MiYOSMART iQ | Single-vision spectacles |
|---|---|---|
| Refractive change (SER) | +0.046D | −0.534D |
| Axial elongation (AL) | 0.075 mm | 0.346 mm |
The MiYOSMART iQ group showed essentially no average increase in short-sightedness during the 12-month observation period.
The single-vision group experienced greater average progression.
The difference in axial elongation was also substantial.
What Does +0.046D Mean?
A group-average refractive change of +0.046D indicates that the MiYOSMART iQ group did not experience increasing short-sightedness on average over the year.
However, this is a group mean.
Some children may have progressed, some may have remained stable and others may have experienced small changes in the opposite direction.
It does not mean existing myopia was cured.
What Does 0.075 mm of Axial Elongation Mean?
The children’s eyes still grew on average.
However, their average axial elongation was smaller than that of the single-vision group.
This is important because myopia management aims to slow excessive eye growth, not necessarily prevent every amount of normal eye growth.
Did Nine Out of Ten Children Stop Progressing?
One of HOYA’s most widely discussed findings is that approximately nine out of ten children wearing MiYOSMART iQ experienced no clinically relevant myopia progression over 12 months.
This is encouraging, but the wording matters.
For the reported study, clinically relevant progression was defined using a spherical equivalent refractive change of at least −0.50D over 12 months.
Children who did not reach that threshold were counted as having no clinically relevant progression.
Therefore, the result does not mean:
- Every one of those children had exactly zero prescription change
- Myopia was permanently stopped
- The children’s existing prescriptions disappeared
- The same outcome is guaranteed for every future patient
Instead, the finding means that approximately 90% of the children wearing MiYOSMART iQ remained below the study’s defined progression threshold during their first year.
For parents, this is a more accurate way to understand the result.
MiYOSMART iQ Results for Younger Children Aged 4–6
One important feature of the MiYOSMART iQ research is that it included children as young as four.
Younger children who develop myopia may have more years during which their prescription can progress.
HOYA reported the following age-specific results.
| Measurement | MiYOSMART iQ | Single-vision spectacles |
|---|---|---|
| Average refractive change | −0.220D | −0.635D |
| Average axial elongation | 0.266 mm | 0.475 mm |
These findings suggest that MiYOSMART iQ may help slow progression in younger children.
However, they should not be interpreted as proof that the lens is suitable for every four-year-old.
The clinical trial’s age range does not automatically establish the approved minimum prescribing age in Malaysia.
Suitability depends on the child’s examination, prescription and applicable product indications.
MiYOSMART iQ Results for Children Aged 7–12
HOYA also reported outcomes specifically for children aged 7–12.
| Measurement | MiYOSMART iQ | Single-vision spectacles |
|---|---|---|
| Average refractive change | +0.155D | −0.511D |
| Average axial elongation | 0.019 mm | 0.310 mm |
These findings indicate a substantial difference in average progression between the study groups.
HOYA described the refractive-control effect as exceeding 100% and reported approximately 94% less axial elongation in this age group.
How Can Myopia Control Exceed 100%?
A percentage above 100% can arise mathematically when the treatment group shows a small average positive refractive change while the control group becomes more myopic.
It does not mean myopia management is more than completely effective for every child.
Nor does it prove permanent reversal of myopia.
The absolute refractive and axial-length measurements are generally more useful than a headline percentage when explaining the findings to parents.
How Reliable Are the Clinical Results?
The MiYOSMART iQ findings are promising, but they should be interpreted carefully.
Strengths of the Research
The study used a randomized controlled design.
It included conventional single-vision spectacles as a comparison.
Researchers measured both prescription progression and axial length.
The trial included younger children who have often been underrepresented in earlier spectacle-lens research.
Important Limitations
The study was conducted among children in Hong Kong.
Results may vary in other populations, ages and clinical circumstances.
The 12-month findings were presented at a scientific conference and supported by HOYA data on file.
They should not be described as a fully peer-reviewed 12-month journal publication unless that publication becomes available.
Longer-term research is also needed to determine whether the observed benefits are sustained over several years.
The original MiYOSMART has a longer established evidence history.
The evidence supports MiYOSMART iQ as a promising new myopia-management spectacle lens, but it does not guarantee the same result for every child.
Why Spectacle-Based Myopia Management Appeals to Malaysian Parents
One practical advantage of MiYOSMART iQ is that it is worn as spectacles.
Children do not need to insert or remove contact lenses.
There is no overnight lens wear or contact lens disinfection routine.
This can be particularly appealing for younger children or families who prefer a familiar daily routine.
Key Benefits
Familiar to children: Children already wearing spectacles may find the transition straightforward.
No contact lens hygiene routine: Parents do not need to supervise lens insertion, removal or disinfection.
Vision correction and myopia management together: The spectacles correct the child’s prescription while delivering the intended optical treatment signals.
Suitable for school routines: Spectacles can be worn during lessons, homework and other everyday activities.
Can be monitored clinically: Prescription and axial-length measurements help assess treatment response.
Important Considerations
Consistent wear remains important.
Frames must fit properly and remain stable.
Some children may need time to adapt to the specialised optical design.
Spectacles may be less convenient for certain sports or activities.
The treatment does not guarantee that myopia progression will stop.
How Does MiYOSMART iQ Compare With Other Myopia-Control Spectacle Lenses?
Several manufacturers have developed specialised spectacle lenses for childhood myopia management.
| Lens | Technology | Main optical approach |
|---|---|---|
| HOYA MiYOSMART iQ | DIMS TED | Triple Enhanced Design with defocus segments |
| HOYA MiYOSMART | D.I.M.S. | Defocus Incorporated Multiple Segments |
| Essilor Stellest | H.A.L.T. | Highly Aspherical Lenslet Target |
| ZEISS MyoCare | C.A.R.E. | Cylindrical Annular Refractive Elements |
| ZEISS MyoActive | M.O.V.E. | Spatially varying myopic-defocus signals |
| VisionXlab H.O.R.I. | Hexagonal optical design | Hexagonal lenslet treatment pattern |
All these technologies aim to help slow myopia progression.
However, their optical designs, study populations and research methods differ.
Effectiveness percentages from separate studies should not be directly ranked as though they came from one head-to-head trial.
The most appropriate lens depends on the child’s clinical needs.
MiYOSMART iQ vs Ortho-K, Soft Contact Lenses and Atropine
Spectacle lenses are one of several approaches to childhood myopia management.
| Treatment | When used | Main consideration |
|---|---|---|
| MiYOSMART iQ | Daytime spectacle wear | No contact lens handling |
| Orthokeratology | Overnight contact lens wear | Requires careful hygiene and professional fitting |
| Soft myopia-management contact lenses | Daytime contact lens wear | Requires contact lens handling |
| Low-dose atropine | As medically prescribed | Requires medical prescribing and monitoring |
No single treatment is suitable for every child.
Some families prefer spectacles because they are familiar and convenient.
Others may benefit from orthokeratology, soft myopia-management contact lenses or medical co-management.
A comprehensive clinical assessment should guide the decision.
Why Malaya Optical Measures Axial Length, Not Just Prescription
At Malaya Optical, we believe myopia management should involve more than updating a child’s spectacle power.
Our optometrists use ocular biometry, including the ARK Biometer Combo, to monitor axial length in our myopia-management patients.
Axial length measures the eye from front to back.
Because excessive axial elongation is closely associated with childhood myopia progression, monitoring this measurement helps us understand how the eye is growing.
What We Monitor
| Measurement | Why it matters |
|---|---|
| Refractive prescription | Tracks changes in short-sightedness |
| Axial length | Measures eye growth |
| Progression rate | Helps identify how quickly myopia is changing |
| Baseline measurements | Provides a reference for future reviews |
| Treatment response | Helps evaluate whether management is having the intended effect |
| Wearing habits | Helps interpret adherence and outcomes |
Why Eye Growth Matters
Imagine two children with the same spectacle prescription of −2.00D.
Both begin myopia management.
After six months, their prescriptions have changed very little.
However, one child’s axial length has increased more than the other’s.
If we only check spectacle power, we may miss an important difference in their eye-growth patterns.
This is why axial-length monitoring provides valuable information alongside refraction.
How Often Should Children Be Reviewed?
A baseline examination should be completed before treatment begins.
Depending on the child’s age, progression and clinical needs, follow-up appointments may be scheduled approximately every three to six months, or at another interval recommended by the optometrist.
During these reviews, our optometrists can assess prescription changes, axial length, spectacle fit, wearing habits, visual comfort and treatment response.
If progression remains faster than expected, the management plan can be reviewed.
Myopia Management for Malaysian Schoolchildren
Children in Malaysia often spend long periods on near-vision activities.
School lessons, homework, tuition, digital learning and recreational screen use can contribute to extended close-up visual demands.
Busy urban routines in Kuala Lumpur, Petaling Jaya, Subang Jaya and Puchong may also limit opportunities for outdoor activity.
However, myopia is influenced by several factors, including genetics, age and environmental exposure.
Screen use alone should not be described as the sole cause.
What Parents Can Do
Encourage regular outdoor activity when practical and safe.
Provide breaks during prolonged near work.
Encourage comfortable reading distances.
Ensure suitable lighting during study.
Schedule regular eye examinations.
Follow the recommended wearing and review schedule for prescribed myopia-management treatments.
These habits support healthy visual routines but do not replace appropriate clinical management when myopia is progressing.
Why Early Detection Matters
Children do not always recognise that their distance vision is becoming blurry.
Parents or teachers may notice squinting, difficulty seeing the classroom board, moving closer to screens or frequent prescription changes.
Malaya Optical has participated in eye-screening programmes at both international and government schools.
These experiences reinforce the importance of identifying possible vision problems early.
School screening can help identify children who need further assessment, but it does not replace a comprehensive eye examination.
Frequently Asked Questions About HOYA MiYOSMART iQ
1. What is HOYA MiYOSMART iQ?
MiYOSMART iQ is a specialised spectacle lens using DIMS Triple Enhanced Design to provide optical signals intended to slow childhood myopia progression.
2. What does DIMS TED stand for?
DIMS TED stands for Defocus Incorporated Multiple Segments with Triple Enhanced Design.
3. How is MiYOSMART iQ different from original MiYOSMART?
MiYOSMART iQ incorporates treatment segments closer to the centre, higher defocus power and a larger treatment area.
4. Is MiYOSMART iQ replacing original MiYOSMART?
Not at Malaya Optical. We plan to continue offering original MiYOSMART alongside MiYOSMART iQ.
5. Is MiYOSMART iQ more effective?
HOYA reports stronger clinical outcomes with the newer design in its research programme. However, individual results vary, and longer-term evidence remains important.
6. Did nine out of ten children stop progressing?
HOYA reported that approximately nine out of ten children showed no clinically relevant progression over one year, using a defined prescription-change threshold. This does not mean every child had absolutely zero change.
7. Can MiYOSMART iQ cure myopia?
No. It corrects existing short-sightedness while aiming to slow further progression.
8. Is MiYOSMART iQ suitable for four-year-old children?
The clinical trial included children as young as four. Suitability depends on the child’s examination and the approved Malaysian product indications.
9. Is MiYOSMART iQ better than Stellest or ZEISS MyoActive?
There is insufficient direct head-to-head evidence to conclude that it is superior for every child.
10. Does my child need to wear MiYOSMART iQ every day?
Consistent daily wear is important. Follow the wearing schedule recommended by the child’s optometrist.
11. Does my child still need regular eye examinations?
Yes. Prescription, axial length, spectacle fit and treatment response should be monitored regularly.
12. Why is axial length important?
Axial length measures eye growth. Monitoring changes helps assess myopia progression and treatment response.
13. Is HOYA MiYOSMART iQ available in Malaysia?
MiYOSMART iQ has been introduced in selected international markets. Malaysian availability and approved specifications should be confirmed locally.
14. Will Malaya Optical offer MiYOSMART iQ?
MiYOSMART iQ is coming soon to Malaya Optical, with planned availability at all four branches.
15. Can my child continue wearing original MiYOSMART?
Yes. Malaya Optical plans to continue offering original MiYOSMART. Whether a child should continue with their current lens or consider another design should be guided by clinical assessment and progression monitoring.
HOYA MiYOSMART iQ Is Coming Soon to Malaya Optical Malaysia
Malaya Optical has been caring for the visual needs of Malaysian families since 1957.
Our approach to childhood myopia management combines comprehensive eye examinations, clinical measurements, appropriate optical technologies and ongoing monitoring.
With a team of optometrists and access to ocular biometry, we focus on understanding each child’s progression rather than simply updating their prescription.
HOYA MiYOSMART iQ is coming soon to all four Malaya Optical branches.
Planned availability includes:
- Malaya Optical Jalan Imbi — Kuala Lumpur
- Malaya Optical Damansara Uptown — Petaling Jaya
- Malaya Optical SS15 — Subang Jaya
- Malaya Optical Bandar Puteri — Puchong
We will also continue offering the original HOYA MiYOSMART, allowing parents to discuss both technologies with our optometrists.
Book a Children’s Myopia Assessment
If your child’s spectacle prescription continues to increase, a comprehensive assessment can help determine the next step.
Our optometrists can evaluate prescription changes, axial length, progression history and visual needs before discussing appropriate myopia-management options.
Book your child’s myopia assessment: https://book.malayaoptical.com
Interested in HOYA MiYOSMART iQ?
Although MiYOSMART iQ is not yet available at our branches, parents are welcome to contact Malaya Optical to enquire about its upcoming availability.
Our team can also discuss currently available myopia-management options while you await the new technology.
Clear vision matters today. Managing myopia progression matters for the years ahead.
Disclaimer: This article provides general educational information and does not replace an individual eye examination or professional clinical advice. Myopia-management outcomes vary between children. HOYA MiYOSMART iQ availability, approved age indications and product specifications in Malaysia should be confirmed before prescribing.
Research References
- HOYA Vision Care. An End to Myopia Progression? New Spectacle Lens Technology Shows 12-Month Clinical Results. 5 May 2026.
https://www.hoyavision.com/about-hoya/hoya-vision-care-news/news/arvo-miyosmart-iq-12-month-clinical-evidence-hoya-vision-care-press-release/ - HOYA Vision Care. MiYOSMART iQ: Six-Month Clinical Evidence. 8 February 2026.
https://www.hoyavision.com/about-hoya/hoya-vision-care-news/news/miyosmart-iq–6-month-clinical-evidence–hoya-vision-care-press-release/ - HOYA Vision Care. MiYOSMART iQ: Product and Technology Information.
https://www.hoyavision.com/vision-products/myopia-management/miyosmart-iq/ - Tse DYY, et al. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Spectacle Lens with Triple Enhanced Design: A 12-Month Randomized Controlled Trial. ARVO 2026, Abstract 2523.
- Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses Slow Myopia Progression: A 2-Year Randomised Clinical Trial. British Journal of Ophthalmology. 2020;104:363–368.
https://doi.org/10.1136/bjophthalmol-2018-313739 - Bullimore MA, et al. The Risks and Benefits of Myopia Control. Ophthalmology. 2021;128(11):1561–1579.